Table 2 Univariable and multivariable analysis: ORR.
Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
Variable | Odds Ratio (95% CI) | P value | Odds ratio (95% CI) | P value |
Age (decades) | 0.95 (0.71–1.27) | 0.74 | 0.92 (0.65–1.31) | 0.65 |
Prior BCMA exposure | ||||
No | 1 | 1 | ||
Yes | 0.49 (0.26–0.91) | 0.02 | 0.47 (0.24–0.94) | 0.03 |
EMD | ||||
No | 1 | 1 | ||
Yes | 0.74 (0.30–1.86) | 0.5 | 1.11 (0.41–3.22) | 0.85 |
Unknown | 0.51 (0.26–0.99) | 0.05 | 0.79 (0.32–1.98) | 0.61 |
ECOG performance status | ||||
ECOG 0 | 1 | 1 | ||
ECOG 1 | 1.33 (0.38–4.16) | 0.64 | 1.47 (0.37–5.37) | 0.57 |
ECOG 2 | 1.00 (0.23–4.35) | 1 | 1.23 (0.23–6.69) | 0.81 |
ECOG 3 | 0.15 (0.02–0.77) | 0.03 | 0.14 (0.02–0.87) | 0.04 |
Unknown | 0.50 (0.15–1.45) | 0.22 | 0.76 (0.18–2.95) | 0.7 |
Cytogenetic Risk | ||||
Standard-risk | 1 | 1 | ||
High-risk | 0.60 (0.30–1.20) | 0.15 | 0.67 (0.31–1.45) | 0.31 |
Unknown | 0.94 (0.4–2.25) | 0.88 | 0.88 (0.33–2.42) | 0.8 |
Platelet count at start of teclistamab | ||||
≥50 × 109/L | 1 | 1 | ||
<50 × 109/L | 0.33 (0.14–0.76) | 0.01 | 0.31 (0.12–0.78) | 0.01 |
Penta-drug refractory | ||||
No | 1 | 1 | ||
Yes | 0.33 (0.15–0.67) | 0.003 | 0.38 (0.16–0.86) | 0.02 |
Unknown | 0.33 (0.14–0.74) | 0.008 | 0.46 (0.16–1.28) | 0.13 |
